Brought to you by 
AZ pays big for some rights to FibroGen's anemia compound FG4592
01 Mar 2019
Executive Summary
AstraZeneca PLC and FibroGen Inc. (therapies for fibrotic diseases) have entered into an agreement for the development and sale of FibroGen’s FG4592 (roxadustat), a candidate for anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). The deal covers the US, China, and other major countries excluding Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa--territories where Astellas Pharma holds rights under a 2006 deal.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ pays big for some rights to FibroGen's anemia compound FG4592
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice